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Several organizations from multiple fields of medicine are setting standards for clinical research 
including protocol development,1 harmonization of outcome reporting,2 statistical analysis,3 
quality assessment4 and reporting of findings.1 Clinical research standardization facilitates the 
interpretation and synthesis of data, increases the usability of trial results for guideline groups 
and shared decision-making, and reduces selective outcome reporting bias.  
 
The mission of the Harmonising Outcome Measures for Eczema (HOME) initiative is to 
establish an agreed-upon core set of outcomes to be measured and reported in all clinical trials of 
atopic dermatitis (AD). Following a systematic approach involving reviews of best evidence and 
consensus voting,5 our group identified two well-validated instruments to measure the core 
domains of signs and symptoms of AD.6, 7 The Eczema Area and Severity Index (EASI) 
measures physician-reported signs,6 and the Patient-Oriented Eczema Measure (POEM) 
measures patient-reported symptoms.7  
 
The objective of this letter is to provide recommendations for the minimum reporting of EASI 
and POEM scores in AD clinical trials with the goal of minimizing bias, improving the quality of 
data synthesis, and facilitating study interpretation by patients, clinicians, and other stakeholders.  
 
While the EASI and POEM are now included as core instruments in most large phase 2 and 3 
clinical trials in AD, reporting of these endpoints is far from standardized. Investigators currently 
report an array of analyses for these endpoints, such as the mean change from baseline, the mean 
of the percentage change from baseline, and dichotomized results using various definitions of 
success versus no success (Supplementary Table 1). While general trial reporting 
recommendations exist, the lack of EASI and POEM specific guidelines hinders communication 
and effective data aggregation for AD trials.  
 
There are several generalized reporting recommendations for clinical trials. The widely accepted 
CONSORT (Consolidated Standards of Reporting Trials) 2010 Statement recommends that trials 
report a summary of outcomes for each study group, such as the mean and standard deviation at 
each time-point, as well as comparison between groups. For trials utilizing continuous variables, 
CONSORT recommends mean difference and 95% confidence interval (CI) when comparing 
groups. Additionally, CONSORT urges investigators to disclose all methods used to analyze data 
to increase transparency and minimize reporting bias.1 With the advent of online publication, 
investigators are no longer constrained by space and are encouraged to include all data and 
explanations in their reports. Thus, trial reporting is trending toward full disclosure of data on an 
individual participant level.8 
 
Recommendations of what to avoid in trials with continuous variables also exist. 
Dichotomization of continuous outcomes and comparing percent change between groups may 
have limited use given the loss of power and difficulty pooling disparate results.9, 10, 11 These two 
methods appear frequently in reporting of EASI scores, likely because they can be easily 
understood by patients or clinicians, and because of historical trends in reporting. 
 
Based on the above literature, we recommend the following EASI and POEM-specific reporting 
recommendations (Table 1). As a minimum, all investigators using these instruments should 
include a baseline mean and standard deviation (SD) and an end of treatment mean and SD for 
individual randomized groups (or median and quartile range for skewed data)1 along with the 
associated number of participants analyzed. For maximal data transparency, these data would 
also be reported for each time-point. For guidance on reporting differences between groups, we 
recommend referencing CONSORT.1  
 
Although guidelines recommend against dichotomizing continuous outcome variables into 
binary results, this has become common in AD literature (e.g. EASI-75) and represents a primary 
endpoint for regulatory approval in the European Union. Percent reduction or proportion of 
patients achieving a minimal important change (MIC) may be clinically useful as well.12 
Including additional ways of reporting EASI and POEM scores such as these is acceptable 
provided the minimum reporting described in Table 1 is also met.  
 
Implementation of the EASI and POEM is becoming standard in AD trials, thus improving the 
ability to pool and compare results in meta-analyses. These reporting recommendations will 
further facilitate standardization in outcome reporting, more accurate data synthesis, and more 
valid data interpretation in all AD trials moving forward.  
 
Table 1. Recommended minimum reporting standards for core outcome measurement 
instruments (EASI and POEM) in atopic dermatitis trials 
SD=Standard Deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Baseline mean and SD for individual randomized groups (or median and quartile range for 
skewed data)  
 End of treatment mean and SD for individual randomized groups (or median and quartile 
range for skewed data) 
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